v3.26.1
Segment Information - Summary of Financial Data for Development of Pharmaceutical Products Segments (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Sep. 30, 2025
Mar. 31, 2025
Dec. 31, 2024
Sep. 30, 2024
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2025
Operating and other (income) expense                  
Employee expenses $ 548     $ 1,585     $ 1,626 $ 8,584  
Other segment expenses 838 [1]     548 [2]     2,525 [3] 2,219 [4]  
Professional fees 409     307     1,908 1,218  
Legal fees 283     331     1,289 1,517  
Asset management fee and advisory fees 675           1,838    
Change in fair value of digital assets 18,845   $ 631 0     45,992 0  
Change in fair value of digital assets receivable, net 2,330     0     3,863 0  
Gain on disposition of nonfinancial asset 0     0     0 (500)  
Gain on derivative liabilities (192)     0     (733) 0  
Interest and dividend income (54) [5]     (202) [6]     (214) [7] (836) [8]  
Total operating and other (income) expense 23,694     2,573     58,132 13,257  
Net (loss) income (23,694) $ (30,799) $ (3,639) (2,573) $ (2,677) $ (8,007) (58,132) (13,257)  
Current assets:                  
Cash and cash equivalents 7,544           7,544   $ 18,011
Prepaid expenses and other current assets 1,347           1,347   274
Digital assets 2,084           2,084   0
Total current assets 10,975           10,975   18,285
Digital assets, net of current portion 38,237           38,237   0
Digital assets - receivable, net 7,899           7,899    
Other long-term assets 678           678   0
Total assets 57,789           57,789   18,285
voruciclib                  
Operating and other (income) expense                  
Other segment expenses 12     4     38 802  
ME-344                  
Operating and other (income) expense                  
Other segment expenses               253  
Operating Segments [Member]                  
Operating and other (income) expense                  
Employee expenses 223           622    
Other segment expenses 26 [1]           64 [3]    
Professional fees 122           565    
Legal fees 181           659    
Asset management fee and advisory fees 675           1,838    
Change in fair value of digital assets 18,845           45,992    
Change in fair value of digital assets receivable, net 2,330           3,863    
Gain on derivative liabilities (192)           (733)    
Interest and dividend income 0 [5]           0 [7]    
Total operating and other (income) expense 22,222           52,908    
Net (loss) income (22,222)           (52,908)    
Current assets:                  
Cash and cash equivalents 0           0    
Prepaid expenses and other current assets 637           637    
Digital assets 2,084           2,084    
Total current assets 2,721           2,721    
Digital assets, net of current portion 38,237           38,237    
Digital assets - receivable, net 7,899           7,899    
Other long-term assets 0           0    
Total assets 48,857           48,857    
Operating Segments [Member] | Digital Asset Treasury Strategy                  
Operating and other (income) expense                  
Employee expenses 212           588    
Other segment expenses 19 [1]           52 [3]    
Professional fees 122           563    
Legal fees 0           112    
Asset management fee and advisory fees 675           1,838    
Change in fair value of digital assets 18,845           45,992    
Change in fair value of digital assets receivable, net 2,330           3,863    
Gain on derivative liabilities (192)           (733)    
Interest and dividend income 0 [5]           0 [7]    
Total operating and other (income) expense 22,011           52,275    
Net (loss) income (22,011)           (52,275)    
Current assets:                  
Cash and cash equivalents 0           0    
Prepaid expenses and other current assets 606           606    
Digital assets 2,084           2,084    
Total current assets 2,690           2,690    
Digital assets, net of current portion 38,237           38,237    
Digital assets - receivable, net 7,899           7,899    
Other long-term assets 0           0    
Total assets 48,826           48,826    
Operating Segments [Member] | Development of Pharmaceutical Products                  
Operating and other (income) expense                  
Employee expenses 11     236     34 2,602  
Other segment expenses 7 [1]     125 [2]     12 [3] 158 [4]  
Professional fees 0     4     2 25  
Legal fees 181     105     547 514  
Asset management fee and advisory fees 0           0    
Change in fair value of digital assets 0           0    
Change in fair value of digital assets receivable, net 0           0    
Gain on disposition of nonfinancial asset               0  
Gain on derivative liabilities 0           0    
Interest and dividend income 0 [5]     0 [6]     0 [7] 0 [8]  
Total operating and other (income) expense 211     474     633 4,354  
Net (loss) income (211)     (474)     (633) (4,354)  
Current assets:                  
Cash and cash equivalents 0           0   0
Prepaid expenses and other current assets 31           31   25
Digital assets 0           0    
Total current assets 31           31   25
Digital assets, net of current portion 0           0    
Digital assets - receivable, net 0           0    
Other long-term assets 0           0    
Total assets 31           31   25
Operating Segments [Member] | voruciclib                  
Operating and other (income) expense                  
Other segment expenses 12           38    
Operating Segments [Member] | voruciclib | Digital Asset Treasury Strategy                  
Operating and other (income) expense                  
Other segment expenses 0           0    
Operating Segments [Member] | voruciclib | Development of Pharmaceutical Products                  
Operating and other (income) expense                  
Other segment expenses 12     4     38 802  
Operating Segments [Member] | ME-344 | Development of Pharmaceutical Products                  
Operating and other (income) expense                  
Other segment expenses               253  
Corporate [Member]                  
Operating and other (income) expense                  
Employee expenses 325     1,349     1,004 5,982  
Other segment expenses 812 [1]     423 [2]     2,461 [3] 2,061 [4]  
Professional fees 287     303     1,343 1,193  
Legal fees 102     226     630 1,003  
Asset management fee and advisory fees 0           0    
Change in fair value of digital assets 0           0    
Change in fair value of digital assets receivable, net 0           0    
Gain on disposition of nonfinancial asset               (500)  
Gain on derivative liabilities 0           0    
Interest and dividend income (54) [5]     (202) [6]     (214) [7] (836) [8]  
Total operating and other (income) expense 1,472     2,099     5,224 8,903  
Net (loss) income (1,472)     (2,099)     (5,224) (8,903)  
Current assets:                  
Cash and cash equivalents 7,544           7,544   18,011
Prepaid expenses and other current assets 710           710   249
Digital assets 0           0    
Total current assets 8,254           8,254   18,260
Digital assets, net of current portion 0           0    
Digital assets - receivable, net 0           0    
Other long-term assets 678           678    
Total assets 8,932           $ 8,932   $ 18,260
Corporate [Member] | voruciclib                  
Operating and other (income) expense                  
Other segment expenses $ 0     $ 0       0  
Corporate [Member] | ME-344                  
Operating and other (income) expense                  
Other segment expenses               $ 0  
[1] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, share-based compensation costs, administrative costs, travel and business taxes.
[2] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.
[3] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, share-based compensation costs, administrative costs, travel and business taxes.
[4] Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.
[5] Interest and dividend income are solely attributable to our cash and cash equivalents.
[6] Interest and dividend income are solely attributable to our cash and cash equivalents.
[7] Interest and dividend income are solely attributable to our cash and cash equivalents.
[8] Interest and dividend income are solely attributable to our cash and cash equivalents.